Eisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...

Kyung Bo Kim discovered compounds that improved cognitive function regardless of amyloid plaque buildup — an encouraging sign ...

New drug approvals and a federal dementia care pilot program among the year's significant developments, according to the ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

New research suggests that commonly used medications like antibiotics, antivirals, and anti-inflammatories could lower the ...

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the ...

EXISTING drugs already dished out on the NHS could slash dementia risk, a new study has revealed. While new drugs are ...

A study analyzing data from over 130 million individuals found that antibiotics, antivirals, vaccines, and anti-inflammatory ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...